“Patients with grade two glioma who had IDH1 mutation treated with Vorasidenib doubled in terms of survival. And it’s a ...

Firefighters show higher rates of glioma-linked SBS42 mutational signatures associated with haloalkane exposure, suggesting ...

Published recently in the journal Frontiers in Nutrition, the report is the first evaluation of the use of ketogenic metabolic therapy (KMT) without chemo or radiation interventions, on a patient ...

New research by Yale has found an association between exposure to chemicals commonly used in firefighting and incidence of a ...

A similar effort would be welcomed in lower grade gliomas, particularly those with IDH1/IDH2mutation and 1p/19q codeletion, more vulnerable to treatment and therefore representing some kind of ...

Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A Multilingual Overview of the INDIGO Study Data (Presented by Clinical Experts in French ...

The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer. The IDH1/2 inhibitor, which can be ...

UCLA co-led study is first trial analyzing a targeted therapy drug specifically made for brain tumors. In an international study co-led by UCLA Health Jonsson Comprehensive Cancer Center ...